Zacks: Analysts Expect Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) to Announce -$2.74 EPS

Share on StockTwits

Wall Street brokerages predict that Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) will post earnings of ($2.74) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Biohaven Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($2.42) and the lowest estimate coming in at ($3.04). Biohaven Pharmaceutical posted earnings of ($2.04) per share during the same quarter last year, which would suggest a negative year over year growth rate of 34.3%. The firm is scheduled to issue its next earnings results on Friday, November 6th.

On average, analysts expect that Biohaven Pharmaceutical will report full-year earnings of ($11.94) per share for the current financial year, with EPS estimates ranging from ($12.45) to ($11.03). For the next financial year, analysts expect that the firm will post earnings of ($8.75) per share, with EPS estimates ranging from ($10.55) to ($7.44). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Biohaven Pharmaceutical.

Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Monday, August 10th. The company reported ($2.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.78) by $0.23. The business had revenue of $9.70 million during the quarter, compared to the consensus estimate of $7.43 million. During the same period last year, the company posted ($2.35) earnings per share.

A number of brokerages have weighed in on BHVN. Wedbush boosted their target price on shares of Biohaven Pharmaceutical from $96.00 to $99.00 and gave the company an “outperform” rating in a research note on Tuesday, October 13th. Morgan Stanley boosted their target price on shares of Biohaven Pharmaceutical from $57.00 to $63.00 and gave the company an “equal weight” rating in a research note on Tuesday, October 13th. Finally, William Blair reiterated a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Monday, August 10th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Biohaven Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $78.55.

In other Biohaven Pharmaceutical news, Director Gregory Bailey sold 24,566 shares of the stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $79.47, for a total value of $1,952,260.02. Following the completion of the sale, the director now owns 2,559,161 shares in the company, valued at approximately $203,376,524.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John W. Childs purchased 6,678 shares of the business’s stock in a transaction on Friday, September 11th. The stock was acquired at an average price of $59.00 per share, with a total value of $394,002.00. Following the purchase, the director now directly owns 2,508,616 shares in the company, valued at approximately $148,008,344. The disclosure for this purchase can be found here. Insiders sold a total of 63,097 shares of company stock valued at $4,932,283 over the last 90 days. 19.10% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the business. Point72 Hong Kong Ltd purchased a new stake in Biohaven Pharmaceutical in the 2nd quarter worth $73,000. PNC Financial Services Group Inc. increased its stake in Biohaven Pharmaceutical by 6,251.9% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,715 shares of the company’s stock worth $124,000 after buying an additional 1,688 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Biohaven Pharmaceutical by 237.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,820 shares of the company’s stock worth $118,000 after buying an additional 1,280 shares in the last quarter. UBS Group AG increased its stake in Biohaven Pharmaceutical by 69.3% in the 2nd quarter. UBS Group AG now owns 1,943 shares of the company’s stock worth $142,000 after buying an additional 795 shares in the last quarter. Finally, First Mercantile Trust Co. purchased a new stake in Biohaven Pharmaceutical in the 2nd quarter worth $157,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

BHVN traded down $1.07 during mid-day trading on Friday, reaching $77.40. 5,819 shares of the company traded hands, compared to its average volume of 791,994. The stock has a market capitalization of $4.68 billion, a P/E ratio of -7.11 and a beta of 1.19. The company’s fifty day moving average price is $69.56 and its 200-day moving average price is $62.92. Biohaven Pharmaceutical has a 52-week low of $26.56 and a 52-week high of $80.00.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Read More: Understanding Specialty Certificates of Deposit

Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.